Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
215 results
  • PARP Inhibition in Cancer: An Update on Clinical Development. [Review]
    Target Oncol 2019Sachdev E, Tabatabai R, … Mita MM
  • PARP (poly(ADP-ribose) polymerase) inhibitors represent a novel class of anti-cancer therapy; they take advantage of synthetic lethality and induce cell death by exploiting a defect in DNA repair. This class of medication was initially evaluated in patients with BRCA-associated tumors, but efficacy was also demonstrated in other populations. Since 2014, four PARP inhibitors have been approved in …
  • Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. [Review]
    Cells 2019; 8(8)Adashek JJ, Jain RK, Zhang J
  • The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant prostate cancer have led to early utilization of potent androgen receptor (AR) signaling inhibitors in treating advanced prostate cancer. There is an unmet need to develop novel therapies beyond targeting AR signaling for metastatic …
  • Activation of Wnt signaling promotes olaparib resistant ovarian cancer. [Journal Article]
    Mol Carcinog 2019; 58(10):1770-1782Yamamoto TM, McMellen A, … Bitler BG
  • Epithelial ovarian cancer (EOC) has one of the highest death to incidence ratios among all cancers. High grade serous ovarian carcinoma (HGSOC) is the most common and deadliest EOC histotype due to the lack of therapeutic options following debulking surgery and platinum/taxane-based chemotherapies. For recurrent chemosensitive HGSOC, poly(ADP)-ribose polymerase inhibitors (PARPi; olaparib, rucapa…
  • A decade of clinical development of PARP inhibitors in perspective. [Journal Article]
    Ann Oncol 2019; 30(9):1437-1447Mateo J, Lord CJ, … de Bono JS
  • Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce tumour-specific vulnerabilities that can be exploited therapeutically. In 2009, a first-in-man clinical trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib clinically …
  • Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. [Review]
    Ther Adv Med Oncol 2019; 11:1758835919849753Ledermann JA, Pujade-Lauraine E
  • Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to date has demonstrated that patients with a BRCAm derive the greatest benefit from PARP inhibitors. However, clinical studies have al…
  • Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. [Journal Article]
    Cancer Manag Res 2019; 11:4371-4390Jiang X, Li W, … Zhang Z
  • Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted agents for the treatment of solid tumors. Concurrent PARP inhibition in Breast Cancer Susceptibility Gene (BRCA)-mutated or homologous recombination-deficient tumor cells can induce "synthetic lethality", which targets two DNA repair pathways and induces serious cytotoxicity to tumor cells without damaging normal cells. Curren…
New Search Next